Radiance
Register
Register
Register

RequestUpdated on 26 June 2025

Developing novel immune modulators for improved outcomes in cancer therapy

Marc Creus

CEO at abbmira therapeutics AG

Basel, Switzerland

About

Abbmira is a Swiss biotech startup open to collaboration with academics, clinicians and companies in the field of preclinical R&D in drug-development, in particular in the area of immuno-oncology.

Organisation

abbmira therapeutics AG

Company (SME, Spin-off, Start-up)

Basel, Switzerland

Similar opportunities

  • Expertise

    Preclinical Immuno-Modulatory Drug Development in Oncology

    • CHE - Chemistry
    • LIF - Life Sciences
    • DOCTORAL NETWORKS: Hosting Doctoral Candidates / Secondments / Trainings
    • POSTDOCTORAL FELLOWSHIPS: Hosting Postdoctoral Candidates / Secondments / Placements

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland

  • Project cooperation

    Preclinical Immuno-modulatory Drug Development in Oncology

    • MSCA-PF2025
    • MSCA-DN2025
    • Proposal Idea
    • Proposal under Development
    • POSTDOCTORAL FELLOWSHIP: Looking for an Institution for Secondment
    • DOCTORAL NETWORK: Looking for Partner/s (Beneficiaries or Associated Partners)

    Marc Creus

    CEO at abbmira therapeutics AG

    Basel, Switzerland

  • Request

    Host Marie Curie fellowship

    Michael Chen

    Professor, Chair of Therapeutic Engineering at The University of Edinburgh

    Edinburgh, United Kingdom